% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • swhitemd50 swhitemd50 Mar 26, 2012 10:15 AM Flag

    New doubts about Gilead

    Check out this article:
    It seems that some financial pundits recognize the serious shortcomings of GS-7977 and the potential of Incivek/VX-222/ribavirin.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Good find.

      Quote relevant passages below:

      [[... By making a few calculations -- I will spare you the details -- I now expect an unexciting 50-60% cure rate from these GS-7977 studies. It looks like Gilead will have to remix the drug cocktail, adding another drug to boost efficacy, to achieve more competitive hepatitis C cure rates. I would remain on the sidelines with regards to Gilead shares.

      Gilead's pain has been Vertex's gain, with the latter's shares up 14% despite underwhelming Incivek prescription data. Vertex is also benefiting from early Phase II results suggesting a triple combination of Incivek, the experimental Vertex drug VX-222 and ribavirin may be potent enough to exclude the use of injectable and difficult-to-tolerate interferon. An interferon-free regimen would be a big positive, especially since there are hints of reduced rash, a key Incivek side effect.
      I'm starting to get my usual Hep C headache, so let's cut to the chase: Bold investors might consider owning Vertex shares into next month's EASL conference. The dynamics are complicated, so I wouldn't suggest a big position. Meanwhile, Gilead seems likely to be stuck in neutral for awhile.]]

      The writer is more pessimistic about 7977 than I have been.

    • Stock price says otherwise. And on heavy volume.

90.63-1.49(-1.62%)Sep 23 4:00 PMEDT